Literature DB >> 28130698

DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive.

Irene Centeno1, Aino Paasinen Sohns2, Miriam Flury1, José A Galván1, Stefan Zahnd1, Viktor H Koelzer1, Lena Sokol1, Heather E Dawson1, Alessandro Lugli1, Gieri Cathomas2, Inti Zlobec3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28130698     DOI： 10.1007/s00428-017-2071-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  11 in total

Review 1.  Tumor budding in colorectal cancer--ready for diagnostic practice?

Authors:  Viktor H Koelzer; Inti Zlobec; Alessandro Lugli
Journal:  Hum Pathol       Date:  2015-09-03       Impact factor: 3.466

2.  Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.

Authors:  D H Jensen; E Dabelsteen; L Specht; A M K Fiehn; M H Therkildsen; L Jønson; J Vikesaa; F C Nielsen; C von Buchwald
Journal:  J Pathol       Date:  2015-06-01       Impact factor: 7.996

3.  APC mutation and tumour budding in colorectal cancer.

Authors:  J R Jass; M Barker; L Fraser; M D Walsh; V L J Whitehall; B Gabrielli; J Young; B A Leggett
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

4.  Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome.

Authors:  Viktor H Koelzer; Katharina Canonica; Heather Dawson; Lena Sokol; Eva Karamitopoulou-Diamantis; Alessandro Lugli; Inti Zlobec
Journal:  Oncoimmunology       Date:  2015-11-09       Impact factor: 8.110

Review 5.  Molecular and pathogenetic aspects of tumor budding in colorectal cancer.

Authors:  Heather Dawson; Alessandro Lugli
Journal:  Front Med (Lausanne)       Date:  2015-03-10

Review 6.  Tumor Budding: The Name is EMT. Partial EMT.

Authors:  Alexandru Dan Grigore; Mohit Kumar Jolly; Dongya Jia; Mary C Farach-Carson; Herbert Levine
Journal:  J Clin Med       Date:  2016-04-29       Impact factor: 4.241

7.  Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.

Authors:  Linde De Smedt; Sofie Palmans; Daan Andel; Olivier Govaere; Bram Boeckx; Dominiek Smeets; Eva Galle; Jasper Wouters; David Barras; Madeleine Suffiotti; Jeroen Dekervel; Thomas Tousseyn; Gert De Hertogh; Hans Prenen; Sabine Tejpar; Diether Lambrechts; Xavier Sagaert
Journal:  Br J Cancer       Date:  2016-11-24       Impact factor: 7.640

8.  Intra-tumor genetic heterogeneity in rectal cancer.

Authors:  Karin M Hardiman; Peter J Ulintz; Rork D Kuick; Daniel H Hovelson; Christopher M Gates; Ashwini Bhasi; Ana Rodrigues Grant; Jianhua Liu; Andi K Cani; Joel K Greenson; Scott A Tomlins; Eric R Fearon
Journal:  Lab Invest       Date:  2015-11-16       Impact factor: 5.662

9.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

10.  VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.

Authors:  Christian Schafroth; José A Galván; Irene Centeno; Viktor H Koelzer; Heather E Dawson; Lena Sokol; Gregor Rieger; Martin D Berger; Marion Hädrich; Robert Rosenberg; Ulrich Nitsche; Beat Schnüriger; Rupert Langer; Daniel Inderbitzin; Alessandro Lugli; Inti Zlobec
Journal:  Oncotarget       Date:  2015-12-08
View more
  8 in total

1.  Tumour budding in colorectal cancer: molecular rationale for clinical translation.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

Review 2.  Tumour budding is a novel marker in breast cancer: the clinical application and future prospects.

Authors:  Ting Huang; Hui Bao; Yu-Hua Meng; Jian-Lin Zhu; Xiao-Dong Chu; Xiao-Li Chu; Jing-Hua Pan
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 3.  Tumour budding and its clinical implications in gastrointestinal cancers.

Authors:  Inti Zlobec; Martin D Berger; Alessandro Lugli
Journal:  Br J Cancer       Date:  2020-06-30       Impact factor: 7.640

Review 4.  Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features.

Authors:  Eva Karamitopoulou
Journal:  Br J Cancer       Date:  2019-05-21       Impact factor: 7.640

Review 5.  RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer.

Authors:  Valeria Maffeis; Lorenzo Nicolè; Rocco Cappellesso
Journal:  Front Oncol       Date:  2019-11-19       Impact factor: 6.244

6.  Prognostic Impact of Tumor Budding on Moroccan Colon Cancer Patients.

Authors:  Fatima El Agy; Sanae El Bardai; Laila Bouguenouch; Nada Lahmidani; Mohammed El Abkari; El Bachir Benjelloun; Abdelmalek Ousadden; Khalid Mazaz; Sidi Adil Ibrahimi; Zineb Benbrahim; Laila Chbani
Journal:  Int J Surg Oncol       Date:  2022-01-21

7.  Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.

Authors:  Anne Trinh; Claudia Lädrach; Heather E Dawson; Sanne Ten Hoorn; Peter J K Kuppen; Marlies S Reimers; Miriam Koopman; Cornelis J A Punt; Alessandro Lugli; Louis Vermeulen; Inti Zlobec
Journal:  Br J Cancer       Date:  2018-11-02       Impact factor: 7.640

8.  Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.

Authors:  Inti Zlobec; Melanie Bächli; Francesca Galuppini; Martin D Berger; Heather E Dawson; Iris D Nagtegaal; Alessandro Lugli
Journal:  Virchows Arch       Date:  2021-04-12       Impact factor: 4.064
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.